Resumen de Investigación

Analyzed using Evidence Intelligence™

Continuous Glucose Monitoring Improves Glycemic Control in Diabetes

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 15 de junio de 2026

Key finding

HbA1c decreased from 8.09% to 7.48% (p < 0.001).

This study examined the impact of continuous glucose monitoring on glycemic control in diabetes patients, finding significant reductions in HbA1c and fasting plasma glucose levels.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study examined the impact of continuous glucose monitoring on glycemic control in diabetes patients, finding significant reductions in HbA1c and fasting plasma glucose levels.

Clinical relevance

Improving glycemic control is crucial for diabetes management, as it can reduce the risk of complications associated with the disease. The significant reductions in HbA1c and fasting plasma glucose suggest that continuous glucose monitoring could be an effective tool for patients and healthcare providers aiming to enhance diabetes care.

Keep in mind

Study design was non-randomized, limiting causal inference. Sample size and demographic details were not specified. Potential confounding factors were not controlled.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Mi-Joon L, Bum-Jeun S, Jae-Hyoung C, Daniela MT, Mariana F, Ionela LS. The Effects of Continuous Glucose Monitoring on Glycemic Control in Patients with Diabetes Mellitus. Life. 2025;15(10):1543. doi:10.3390/life15101543

View DOI View on PubMed View on PMC

Efectos Principales

HbA1c decreased from 8.09% to 7.48% (p < 0.001)

Fasting plasma glucose decreased from 152.41 mg/dL to 137.16 mg/dL (p < 0.001)

Total cholesterol decreased from 149.77 mg/dL to 146.95 mg/dL (p = 0.036)

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Continuous glucose monitoring and BMI, Fasting blood sugar (FBS), HbA1c, and 1 more.

This study contributes evidence to

Intervention

Continuous glucose monitoring

Outcome

BMI

Evidence topic

Fasting Blood Glucose

Primary intervention

Continuous glucose monitoring

Primary outcomes

BMI
Fasting blood sugar (FBS)
HbA1c

Evidence topics

Fasting Blood Glucose Glycemic Control HbA1c Reduction Weight Loss

Primary intervention

Continuous glucose monitoring

Primary outcomes

BMI Fasting blood sugar (FBS)HbA1c

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 4 evidence relationships
Includes primary outcome data
Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

Insulin Delivery Systems and HbA1c

Evidencia relacionada

Relación de evidencia

Insulin Delivery Systems and Fasting Glucose

Guardar evidencia

Relación de evidencia

Insulin Delivery Systems and Body Mass Index

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

BMI

Continuous glucose monitoring → BMI

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 67; Slightly Positive
ConsistencyScore™: 67; generally_consistent

Basado en 3 estudios

Add to Evidence Tracker

Fasting blood sugar (FBS)

Continuous glucose monitoring → Fasting blood sugar (FBS)

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

HbA1c

Continuous glucose monitoring → HbA1c

Evidence Intelligence™

EvidenceScore™: 85; Strong
ImpactScore™: 81; Positive
ConsistencyScore™: 85; consistent

Basado en 13 estudios

Add to Evidence Tracker

Total cholesterol

Continuous glucose monitoring → Total cholesterol

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

HbA1c decreased by 0.61% (p < 0.001).
Fasting plasma glucose decreased by 15.25 mg/dL (p < 0.001).
Total cholesterol decreased by 2.82 mg/dL (p = 0.036).

A quién se aplica

Adults diagnosed with diabetes mellitus.
Patients using continuous glucose monitoring devices.

Tener en Cuenta

Results may not be generalizable to all diabetes populations.
The increase in body mass index was not statistically significant.
Further research is needed to confirm long-term effects.

Entre Líneas

Study design was non-randomized, limiting causal inference.
Sample size and demographic details were not specified.
Potential confounding factors were not controlled.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on Insulin Delivery Systems and HbA1c, Insulin Delivery Systems and Body Mass Index.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Devices & Technology

Detailed evidence

Insulin Delivery Systems → HbA1c

Devices & Technology

Evidence Intelligence™

EvidenceScore™: 85; Strong
ImpactScore™: 81; Positive
ConsistencyScore™: 85; consistent

Basado en 13 estudios

View evidence

Devices & Technology

Detailed evidence

Insulin Delivery Systems → Body Mass Index

Devices & Technology

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 67; Slightly Positive
ConsistencyScore™: 67; generally_consistent

Basado en 3 estudios

View evidence

Devices & Technology

Detailed evidence

Insulin Delivery Systems → Adipokine and Angiogenic Markers

Devices & Technology

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Basado en 1 estudio

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

HbA1c Evidence Hub

All studies measuring HbA1c

13 studies

outcome_hub

Measures HbA1c as a key outcome.

Insulin Delivery Systems Evidence Hub

All studies on Insulin Delivery Systems

13 studies

intervention_hub

Contributes to Insulin Delivery Systems evidence base.

Body Mass Index Evidence Hub

All studies measuring Body Mass Index

3 studies

outcome_hub

Measures Body Mass Index as a key outcome.

Adipokine and Angiogenic Markers Evidence Hub

All studies measuring Adipokine and Angiogenic Markers

1 studies

outcome_hub

Measures Adipokine and Angiogenic Markers as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Continuous glucose monitoring and HbA1c

Intervention: Continuous glucose monitoringOutcome: HbA1c

13 results

All studies on Continuous glucose monitoring and BMI

Intervention: Continuous glucose monitoringOutcome: BMI

3 results

All studies on Continuous glucose monitoring

Intervention: Continuous glucose monitoring

13 results

All studies measuring HbA1c

Outcome: HbA1c

13 results

All studies measuring BMI

Outcome: BMI

3 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Delivery Systems lower HbA1c?

Strong Evidence

Insulin Delivery Systems appears to lower HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 21 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Does Insulin Delivery Systems improve fasting glucose?

Strong Evidence

Insulin Delivery Systems may improve fasting glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.

View Full Evidence

Does Insulin Delivery Systems affect body mass index?

Strong Evidence

Insulin Delivery Systems may affect body mass index.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.

View Full Evidence

Does Insulin Delivery Systems improve adipokine and angiogenic markers?

Moderate Evidence

Insulin Delivery Systems appears to improve adipokine and angiogenic markers.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

Only a small number of supporting studies are available.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Fasting Blood Glucose Evidence Hub Glycemic Control Evidence Hub HbA1c Reduction Evidence Hub Weight Loss Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Continuous glucose monitoring and HbA1c All studies on Continuous glucose monitoring and Fasting blood sugar (FBS)All studies on Continuous glucose monitoring and Total cholesterol All studies on Continuous glucose monitoring and BMI

Related research

Read related research summaries.

Caloric restriction improves glycemic control Real-Time CGM Improves Glycemic Control in Type 2 Diabetes Video education improves dietary compliance for diabetes RT-CGM improves glucose control in adults with T2D i3 CGM shows reliable performance for diabetes management

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.